1.Date of occurrence of the event: 2021/11/26
2.Company name: OBI Pharma Inc.
3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office
4.Reciprocal shareholding ratios: No applicable
5.Cause of occurrence: The Company’s Board of Directors resolved to in-license a preclinical discovery project from a biotechnology company specialized in novel cancer therapeutics. The licensing will be kept confidential temporary according to the non-disclosure agreement. Further announcement will be made once the Company finished signing the contract.
6.Countermeasures: None
7.Any other matters that need to be specified: New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks. The investors are advised to exercise caution and conduct thorough evaluation.